Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck has exceeded earnings estimates driven by strong performance from its Keytruda drug and has adjusted its profit outlook to reflect lower anticipated costs from tariffs. This positive adjustment indicates a more favorable financial environment for the company moving forward.